MESA LABORATORIES INC /CO/
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the quarter ended* March 31, 2026,each of Chief Financial Officer John V. Sakys, Senior Vice President of Continuous Improvement Brian Archbold, and Chief Accounting Officer Lyndsey Crennen entered into a written plan for the sale of Mesa's securities intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (each, a "Rule10b5*-1 trading arrangement"). Each Rule10b5-1 trading arrangement was adopted on* March 12, 2026solely to satisfy tax withholding obligations arising from the vesting of equity awards andexpired on June 30, 2026.The Rule10b5*-1 trading arrangements provided for the sale of approximately 4,095,3,695 and 554 shares of Mesa's common stock for Messrs. Sakys and Archbold and Ms. Crennen, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.